KDOQI (Kidney Disease Outcomes Quality Initiative)
NKF KDOQI GUIDELINES

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease


WORK GROUP BIOGRAPHIES

John W. Adamson, MD, has served as Executive Vice President for Research and Director of the Blood Research Institute of the Blood Center of Southeastern Wisconsin in Milwaukee since 1998. He holds the position of Professor of Medicine (Hematology) at the Medical College of Wisconsin. Before moving to Milwaukee, he was Director of the Lindsley F. Kimball Research Institute of the New York Blood Center since 1989 and President of the Center from 1989 to 1997. Dr Adamson received his MD from the University of California, Los Angeles, after which he trained at the University of Washington in Seattle and at the National Institutes of Health in Bethesda, MD, in the fields of internal medicine and hematology. Before assuming his position in New York, Dr Adamson was professor of medicine and head of the Division of Hematology at the University of Washington. Dr Adamson is a past-President of the American Society of Hematology and past chairman of its committees on scientific affairs and transfusion medicine. Dr Adamson served as a member of the Advisory Council of the National Institute of Diabetes, Digestive and Kidney Diseases of the National Institutes of Health. In 1988, he was designated clinical research professor by the American Cancer Society and elected a Fellow of the American Association for the Advancement of Science. Dr Adamson is past editor-in-chief of Blood, past editor of the Journal of Cellular Physiology, and founding editor of Current Opinion in Hematology. Altogether, he has authored or co-authored more than 400 scientific publications. Dr Adamson has received research funds, grants, or contracts from Watson Pharmaceuticals and Navigant Biotechnologies.

George R. Bailie, MSc, PharmD, PhD, is Professor of Pharmacy Practice at Albany College of Pharmacy. He has 20 years of experience in teaching, practice, and research in pharmacotherapeutics and pharmacokinetics in CKD and dialysis. He has published more than 100 original research papers, plus numerous chapters, abstracts, reviews, and cases in the medical and pharmacy literature. He has served on the editorial board and is a regular reviewer for many pharmacy and nephrology journals. Dr Bailie is a member of the Advisory Board for the NKF-KDOQI. He was a member of the KDOQI Work Group that developed the guidelines for Blood Pressure and Antihypertensive Agents in CKD. He is a member of the International Society of Peritoneal Dialysis' Work Group for the Management of Peritonitis. He was designated Fellow of the Royal Pharmaceutical Society of Great Britain for his sustained contributions to the literature of pharmacy and is a Fellow of the American Society of Nephrology. He is a director of Nephrology Pharmacy Associates, Inc, a private consulting company. Dr Bailie has received research funds, grants or contracts from Renal Research Institute, American Regent, Genzyme and Omnicare.

Jeffrey S. Berns, MD, earned his MD at Case Western Reserve University, then went on to complete his internship and residency in Internal Medicine at University Hospitals of Cleveland. He did a fellowship in Nephrology and was an Associate Research Scientist in the Department of Physiology at Yale University. Dr Berns recently was promoted to Professor of Medicine at the University of Pennsylvania School of Medicine, where he is Director of Clinical Nephrology and Director of the Renal Fellowship Program for the Renal, Electrolyte and Hypertension Division. Dr Berns was a member of the NKF-DOQI and KDOQI Anemia Workgroup. He has published and lectured on topics related to chronic kidney disease, anemia management in patients with CKD, and other areas in clinical nephrology. He is co-editor of Drug Prescribing in Renal Failure-Dosing Guidelines for Adults. He also serves on the editorial board of Seminars in Dialysis, American Journal of Kidney Diseases,and Clinical Journal of the American Society of Nephrology. He is an active investigator in clinical trials related to anemia treatment in patients with CKD. Dr Berns has received research funds, grants or contracts from Hoffman La Roche, Ortho Biotech, Advanced Magnetics, Inc., and Amgen.

Kai-Uwe Eckardt, MD (Work Group Co-Chair), is Professor of Medicine and Chief of Nephrology and Hypertension at the University of Erlangen–Nuremberg, Germany. He received his MD from the Westfälische Wilhelms-Universität Münster, Germany. In 1993, following postgraduate training in internal medicine, pathology, and physiology, he was appointed Assistant Professor of Physiology at the University of Regensburg, Germany. Subsequently, he continued his training in internal medicine and nephrology at the Charité, Humboldt University in Berlin, where he was appointed Associate Professor of Nephrology in 2000. His major scientific interests are in the molecular mechanisms and physiological/pathophysiological relevance of oxygen sensing and the management of anemia. Professor Eckardt is Subject Editor of Nephrology, Dialysis and Transplantation and serves on the editorial board of several other journals. He contributed to the development of the EBPGs for Anemia Management and is a member of the executive committee of KDIGO. Dr Eckardt has received research funds, grants or contracts from the German Research Organization. Additionally, Dr Eckardt has received lecture and consultant fees from Amgen, Roche, Johnson & Johnson, and Affymax. He is also associated with CREATE and TREAT studies.

Steven Fishbane, MD, currently is Chief of Nephrology and Associate Chair of the Department of Medicine at Winthrop-University Hospital (WUH) in Mineola, NY, as well as Professor of Medicine at SUNY Stony Brook School of Medicine. He is the Medical Director of WUH Dialysis Network, which includes 4 outpatient dialysis units and 3 hospital units. Dr Fishbane serves as the Chairman of the Long Island Health Network Quality Council; Chairman of the Department of Medicine Quality Improvement Program, WUH; Chairman of Clinical Guidelines Committee, WUH; Co-Chairman of WUH Patient Care Committee; and Associate Chairman of the Department of Medicine, WUH. Dr Fishbane is a member of the Network 2 Medical Review Board. Dr Fishbane has received research funds, grants or contracts from Shire Inc., Amgen Inc., Abbott Labs Inc., Roche Inc., and Watson Inc. Additionally, Dr Fishbane is associated with Ortho Biotech and Watson Pharmaceuticals.

Robert N. Foley, MD, was born in Ireland and received his undergraduate MD from University College Cork. He completed Internal Medicine training in Cork, later moving to Saint John's, Newfoundland, Canada, where he completed a residency in nephrology, as well as a Masters in Clinical Epidemiology. From 1999 to 2002, Dr Foley worked at Hope Hospital, Salford, UK, and has been Director, Nephrology Analytical Services, Minneapolis Medical Research Foundation since September of 2002. Dr Foley also is a Co-Editor of the American Journal of Kidney Diseases. His major interest is in outcomes research, especially the interplay of cardiovascular and renal disease. Dr Foley is active in anemia correction trials, as well as in the USRDS Cardiovascular Special Study Center. Dr Foley has received research funds, grants or contracts from Ortho Biotech, Amgen and Roche.

Sana Ghaddar, PhD, RD, is an Assistant Professor at the American University of Beirut, Lebanon. She has over 10 years experience in the renal and clinical dietetics field. She was one of the renal dietitians at the Peninsula Nephrology Inc., in San Mateo, CA, currently a division of Satellite Healthcare, and has served as a Principle Investigator for two research studies that examined the ability of heme-iron-polypeptide to sustain response to Recombinant Erythropoietin in both hemo and peritoneal dialysis patients. She has presented these and other studies she has been involved in at many national conferences, including National Kidney Foundation, American Dietetics Association and Gerontological Society of America. Dr Ghaddar has received research funds, grants or contracts from the American University of Beirut Research Board. Additionally, Dr Ghaddar is associated with the Kidney Nutrition Education & Life Improvement (K/NELI) study funded by the American Univesity of Beirut.

John S. Gill, MD, MS, obtained his MD from the University of British Columbia (UBC) in 1995. He completed his internal medicine training at the University of Western Ontario in 1998 and his nephrology training in 2000 at UBC. He then completed his transplantation training at Tufts–New England Medical Center in Boston and obtained in Masters in Clinical Care Research from Tufts in 2002. Dr Gill currently is assistant professor of medicine in the division of Nephrology at UBC and has a cross appointment at Tuft–New England Medical Center. Dr Gill's research interests focus on clinical outcomes in kidney transplant recipients. He is the principal investigator and co-investigator on current Canadian Institutes of Health Research (CIHR), Kidney Foundation, and Michael Smith Funded studies. Dr Gill is chair of the Canadian Society of Transplantation Work Group for Pan-Canadian database development, member of the Canadian Organ Replacement Register Advisory Board, and member of a number of NKF Committees. Dr Gill received research funds, grants or contracts from the Michael Smith Foundation for Health Research, the Canadian Institute for Health Research, Wyeth Pharmaceuticals, and Roche Pharmaceuticals.

Kathy Jabs, MD, is a Pediatric Nephrologist who trained at Babies Hospital, NY, and Children's Hospital, Boston. She has been a faculty member at Children's in Boston (1988 to 1996) and was the Director of Dialysis and Renal Transplantation at Children's Hospital of Philadelphia (1996 to 2000). She currently is the Director of Pediatric Nephrology at Vanderbilt Children's Hospital and an Associate Professor of Pediatrics at Vanderbilt University School of Medicine, Nashville, TN. Dr Jabs has had a long-standing interest in the care of children with CKD. Dr Jabs has received research funds, grants or contracts from King Pharmaceuticals and Watson Pharmaceuticals. Additionally, Dr Jabs is associated with the CKid and FSGS studies sponsored by the NIH.

Francesco Locatelli, MD,
is Scientific Director and Head of the Department of Nephrology and Dialysis of A. Manzoni Hospital, Lecco, and Postgraduate Professor of Nephrology at Brescia and Milan Universities in Italy. He is past-President of the European Renal Association–European Dialysis and Transplantation Association, Italian Society of Nephrology, and International Society of Blood Purification and was Chairman of the EBPGs.

Iain C. Macdougall, MD, is a combined medical and science graduate of Glasgow University, Scotland, from which he was awarded a First Class Honours BSc in Pharmacology in 1980. For the last 10 years, Dr Macdougall has been Consultant Nephrologist and Honorary Senior Lecturer at King's College Hospital in London. He has developed both a clinical and a basic science research interest in factors affecting responsiveness to erythropoietic agents. He has served on the Working Parties responsible for both (1999 and 2004) EBPGs on Renal Anaemia Management, and he currently is a member of the US Anemia Guidelines Working Group, the KDIGO Board of Directors, the Global Scientific Advisory Board for PRCA, and the Council of the European Renal Association. He is frequently invited to lecture both nationally and internationally on this topic, and he has co-authored the section on renal anaemia for the last 2 editions of the Oxford Textbook of Clinical Nephrology and the current edition of Comprehensive Clinical Nephrology. He also is Subject Editor for Nephrology Dialysis Transplantation. Dr Macdougall has received research funds, grants or contracts from Amgen, Hoffman La Roche, Affymax, Vifor, and Johnson & Johnson. Additionally, Dr Macdougall is associated with the CERA (Phase III), OPUS, Hematide (Phase II), TREAT (Phase IV) studies sponsored by Roche, Amgen, Affymax, and Amgen, respectively.

Patricia Bargo McCarley, RN, MSN, NP, is a nephrology nurse practitioner at Diablo Nephrology Medical Group in Walnut Creek, California. Ms. McCarley received her BSN and MSN from Vanderbilt University. She is active in ANNA having served on local, regional and national committees. She is currently a member of the Nephrology Nursing Journal Board. Ms. McCarley has authored many publications including most recently chapters in the 2005 ANNA Nephrology Nursing Standards of Practice and Guidelines for Care and the Contemporary Nephrology Nursing: Principles and Practice (2nd Ed.). Dr McCarley has received research funds, grants or contracts from Amgen, Ortho Biotech and Renal Care Group.

Hans H. Messner, MD, is the Director of the Blood and Marrow Program at the Princess Margaret Hospital. He has a long-standing interest in exploring the role of transplantation in the management of patients with various hematopoietic diseases. In the laboratory, he has used culture techniques to examine normal and malignant hematopoietic progenitor cell populations. In the recent past, he has been involved in the establishment of a cell-processing facility at the Princess Margaret Hospital that meets the standards of good manufacturing practices (GMP). This laboratory will facilitate clinical skill of cell separation procedures, cell expansions, and vector transactions into relevant cell populations. This technology also will be instrumental in faciliting explorations of regenerative capability of stem cells for other organ systems. Dr Messner has received research funds, grants or contracts from Ortho Biotech.

Allen R. Nissenson, MD, FACP, is Professor of Medicine and Director of the Dialysis Program at the David Geffen School of Medicine at UCLA, where he has developed a comprehensive dialysis program. He is President of the National Anemia Action Council (NAAC) and recently chaired a Chancellor's committee at UCLA on Financial Conflicts of Interest in Clinical Research. He currently is serving on a University of California Task Force on Institutional Conflicts of Interest in Research. Dr Nissenson is Chair of the Faculty Executive Council for the David Geffen School of Medicine at UCLA. He has served as Chair of the Southern California ESRD Network during its organizational years in the early 1980s and recently was elected as President-elect. He is Chair of the Medical Review Board. Dr Nissenson currently is consulting for RMS Disease Management, Inc and for Philtre, Ltd, an organization developing new renal replacement therapies based on the application of nanotechnology to this field. Dr Nissenson served as a Robert Wood Johnson Health Policy Fellow of the Institute of Medicine in 1994 to 1995. He is Immediate Past President of the Renal Physicians Association and has served as a member of the Advisory Group overseeing the entire NKF-DOQI, as well as serving as a member of the anemia Work Group. Dr Nissenson's major research interests focus on the quality of care for patients with CKD. His research has included extensive clinical trials of new devices and drugs related to renal disease. Dr Nissenson is co-principal investigator on a recently obtained National Institutes of Health Center Grant looking at issues of disparities in health care delivery for patients with CKD. He is the author of 2 dialysis textbooks, both in their fourth editions, and was the founding Editor-in-Chief of Advances in Renal Replacement Therapy, an official journal of the NKF. He currently is Editor-in-Chief of Hemodialysis International, the official journal of the International Society for Hemodialysis. He has more than 340 publications in the field of nephrology, dialysis, anemia management, and health care delivery and policy. Among his numerous honors is the President's Award of the NKF. He delivers more than 25 invited lectures each year and developed and chairs an annual second-year nephrology fellows preceptorship program, serving more than 65 Fellows from throughout the United States. Dr Nissenson has received research funds, grants or contracts from Amgen, Ortho Biotech, Roche, Watson and ARL.

Gregorio T. Obrador, MD, MPH, is Professor of Medicine and Dean at the Universidad Panamericana School of Medicine in Mexico City. He also serves as Adjunct Staff at the Division of Nephrology of the Tufts–New England Medical Center and Assistant Professor of Medicine at the Tufts University School of Medicine in Boston. While doing a clinical research fellowship at the Tufts–New England Medical Center and a Master of Public Health at Harvard University, he began a line of investigation in the area of CKD. Through several publications, he and others showed that the pre–ESRD management of patients with CKD is suboptimal, and that this is an important factor for the high morbidity and mortality observed in these patients. A particular area of interest has been anemia management before the initiation of dialysis therapy. By using population registry data, he and his colleagues have reported trends in anemia and iron management. Dr Obrador has served as reviewer for several journals, including Kidney International, the Journal of the American Society of Nephrology, and the American Journal of Kidney Diseases. He also has been a member of the Advisory Board of the NKF-KDOQI. Dr Obrador has received research funds, grants or contracts from Amgen, and is associated with the TREAT study.

John C. Stivelman, MD, is Chief Medical Officer of the Northwest Kidney Centers and Associate Professor of Medicine in the Division of Nephrology, Department of Medicine, at the University of Washington School of Medicine in Seattle. Dr Stivelman obtained his MD degree from the University of Pennsylvania, completed his residency in Internal Medicine at Harbor-UCLA Medical Center, and nephrology training at Brigham and Women's Hospital. Dr Stivelman has been involved in investigative efforts to optimize hematopoietic therapy for dialysis patients since the phase III recombinant erythropoietin trials in 1986. His major interests and literature contributions center on iron utilization, mechanisms of resistance of erythropoietin therapy, improved dialytic survival in disadvantaged populations, and the interaction of regulatory issues with optimization of care. Dr Stivelman has served as the Chair of the Network 6 Medical Review Board and a member of the Forum of ESRD Networks Board of Directors. He currently serves as medical director of one of Northwest Kidney Centers' free-standing facilities and as a member of the Boards of Directors of the Renal Physicians' Association and the Northwest Renal Network (Network 16). Dr Stivelman has received research funds, grants or contracts from Watson, Amgen and Shire.

David B. Van Wyck, MD (Work Group Co-Chair), is Professor of Medicine and Surgery at the University of Arizona College of Medicine in Tucson. After completing his undergraduate studies at Washington University, St Louis, Dr Van Wyck earned his MD at the University of Arizona College of Medicine. There, he undertook a research fellowship in Surgical Biology and completed his residency in Internal Medicine and fellowship in Nephrology. Dr Van Wyck has written or contributed to books, book chapters, articles, and abstracts on basic iron metabolism and reticuloendothelial function and on clinical aspects of iron and anemia in patients with CKD. On the subject of anemia and kidney disease, he pursues research, provides consultation to industry including American Regent, Amgen, and Gambro Healthcare, and reviews manuscripts for the major nephrology journals. Dr Van Wyck served on the original KDOQI Anemia Work Group. He assumed Chair responsibilities in 2002. Frequently invited to speak, Dr Van Wyck has lectured on the molecular and cellular control of erythropoiesis and iron homeostasis, diagnostic and treatment issues in anemia and iron management, protocol development in the treatment of dialysis-associated anemia, and new approaches to iron and erythropoietin replacement therapy. Dr Van Wyck has received research funds, grants or contracts from Amgen Inc., American Regent Inc., Gambro Healthcare and Shire Pharmaceuticals.

Colin T. White, MD, is a pediatric nephrologist at BC Children's Hospital in Vancouver and clinical assistant professor at the University of British Columbia in Canada. He completed medical school in Ottawa and Pediatrics in London, Ontario. There, he did 3 years of pediatric nephrology training before moving to Vancouver to complete 3 more years. He has been on staff as a Pediatric Nephrologist since 2003 and currently is the Director of Dialysis at BC Children's Hospital. He has a number of research interests, including medical education, optimizing dialysis care in children, estimation of GFR, and CKD and its complications. Dr White's interest in anemia management is geared toward children. He is presently completing a Masters degree in Medical Education. Dr White is associated with the CKid study and various NAPRTC protocols.